#Dry Eye Syndrome Treatment Market 2023

[neha24blog]

Dry Eye Syndrome Treatment Market Analysis By Type, Drug, Product, Dosage Form, Sales Channel, Distribution Channel, Region And Forecast To 2030  : Grand View Research Inc.

San Francisco, 14 Aug 2023: The Report Dry Eye Syndrome Treatment Market Size, Share & Trends Analysis Report By Type (Evaporative, Aqueous Deficient), By Drug, By Product, By Dosage Form, By Sales Channel, By Distribution Channel, By Region, And Segment Forecasts, 2023 – 2030 The global dry eye syndrome treatment market size is expected to reach USD 10.13 billion by 2030, according to a new…

[lasikcomplications]

Lasik Complications

I created this account to share my story with Lasik. I hope my experience informs others of the truth behind the Lasik industry—its deceptive marketing practices, medical negligence culture and hidden complication rates.

I got Wavefront Optimized Lasik in 2023 with the ex500 laser with an Ivy League faculty surgeon in the USA. My myopia was between -5.00 and -6.00 in both eyes beforehand. My astigmatism was minor and uncorrected beforehand, between -.25 and -.50. I actually didn’t even know I had astigmatism before getting Lasik. Since that is a normal amount for most people, it is not noticeable or corrected. My prescription had been stable for over 3 years before proceeding with Lasik.

I have many complications after Lasik and it has been traumatic both physically and mentally. It is singlehandedly the most devastating thing to ever happen to me.

The surgeon should be discussing the risks with you in relation to your specific screening and eye health history during the initial consultation, but the problem is that many do not, rather they just send you a consent form after approving you as a candidate, without explaining why thoroughly. It is solely up to you to educate and inform yourself of the risks beforehand, but you are not an expert in the field so may not know what to look for in your own research.

Below are the things I wish I had known before going through with the procedure.

1) The risk of ectasia in relation to your individual screening results (corneal thickness, age, prescription, etc.). How corneal thickness impacts possibility of retreatment down the line if needed, how further treatment would greatly increase the risk of ectasia by further thinning the cornea. The risk is also very dependent on your current prescription and current corneal thickness. Higher prescriptions require more tissue removal.

2) Dry eye risk in relation to your screening. Explanation of how Lasik severs nerves which causes dry eye, risk of corneal neuralgia if nerves do not heal adequately. Explanation of how nerves never return to preoperative levels.

3) Loss of best achieved/corrected visual acuity and loss of contrast particularly at night due to pupil dilation.

4) Risk of starbursts/halos at night in relation to the patient’s pupil size vs. treatment zone.

5) Risk of under and overcorrection, and irregular astigmatism.

6) Explanation of what the Lasik flap is, scarring risk and permanent loss of corneal strength. Comparison of risks to other procedures: PRK and Smile.

7) Risk of floaters in relation to myopia, lattice degeneration, and risk of retinal detachment or early posterior vitreous detachment due to trauma caused by suction used during procedure. 

8) Risk of rainbow glare due to laser pattern.

9) Explanation of how Lasik increases higher order aberrations which are uncorrectable through regular glasses/soft contacts and lead to visual side effects such as irregular starbursts, etc. There is no guaranteed fix--one can try topography guided retreatment, but it may not work. Scleral lenses can potentially correct but not cure.

10) Explanation of how Lasik makes cataract surgery harder to get if needed down the line. Patients getting Lasik should hold onto all previous eye records and topography scan for future cataract surgery. 11) Explanation of how Lasik leads to falsely low IOP measurements which may increase risk of undiagnosed glaucoma

Of these possible short-term and long-term risks, I currently have the following.

Rainbow glare, a rare side effect caused by the laser pattern. Usually transient over 2 years but not for all. Retreatment can fix it but cannot do due to post-Lasik dry eye syndrome and suspected corneal neuralgia.

Massive, irregular starbursts and halos at night, making night vision significantly poorer than before. I was told after the procedure during a second opinion consultation that I have larger than average dilated pupils, causing light to enter the untreated area at night which causes these visual disturbances. Only temporary pupil constriction drops can treat it, or risk topography-guided retreatment to widen the treatment zone, which may not work either. I'm not sure why I was approved for Lasik given my pupil size, but they told me nothing.

Diagnosed under correction, diagnosed worsened astigmatism after the procedure by .50 diopters in left eye

Diagnosed severe flap scarring

Diagnosed Higher order aberrations (HOAs). Spherical and coma in particular as shown by aberrometry. In only one eye I see diagonal streaks of lights on cars even during the day time, and ghosting at night making it hard to read subtitles, digital clocks, any text on dark screens (can no longer use my phone in dark mode, for example). I also see starbursts and halos at all times of day but they are massive at night. Again, HOAs cannot be easily corrected. Topography guided retreatment may or may not fix it, could make it worse, and scleral lenses may or may not help.

Floaters: I thought I had retinal detachment given all the floaters gradually appearing 1-3 months after Lasik, so I had an emergency appointment. The ophthalmologists cannot explain definitively why Lasik causes more floaters. I have been told that Lasik may just make them clearer. Another has said that the suction during the procedure stirs them up, and may damage the retina. Another has said that Lasik isn’t “supposed” to cause floaters the way cataract surgery does. But no one could provide a concrete answer. However, studies show that Lasik can lead to early Posterior Vitreous Detachment and and Retinal Detachment is a known risk of Lasik, so damage to the retina caused by the suction makes the most sense. In the most recent laser information, all of these are now listed as side effect so I was lied to.

Post-Lasik dry eye and corneal neuralgia. My nerves may or may not regrow adequately over the course of 18 months. I am currently being treated with serum tears which cost around $300 (not covered by insurance) for a 3-month supply. Serum tears are made from your own blood. Another treatment option is IPL which can be around $450 a session (also not covered by insurance). Previously tried prescription Xiidra eyedrops which is around $60 a month with insurance. Before Lasik, I rarely used eye drops. I now use them daily alongside frequent painkillers, nerve medication (Gabapentin), warm compresses and icepacks. I was told I likely had Dry Eye Syndrome before Lasik by an outside eye doctor, but wasn’t aware. I had thought I was becoming intolerant of contact lenses due to allergies. The ophthalmologist should have seen my dry eye during the Lasik screening, but if they did, they didn’t say anything and still approved me as a candidate. Many doctors will also say that Lasik “only causes dry eyes for the first few months,” but this is not true for many people. Some develop long-term or permanent dry eye syndrome and corneal neuralgia due to poor nerve regeneration. My life is very different than it was 8 months ago due to the daily discomfort and pain caused by dry eyes. This is the most devastating impact of Lasik so far. I would strongly advise against getting Lasik if you already have dry eye symptoms.

All this to say, I also knew around 10 people who got Lasik, PRK or Smile before I went through with it, and none had serious complications. Only one regretted the procedure due to regressing with his astigmatism a few years later. Another got Lasik in 2000 for -4.00 myopia and is still 20/20 today without side effects.

But given my side effects, I am shocked to be the “1 in 11.” I have wondered if the statistics are really accurate that most fare well. Even if I am the unlucky one, the 1 in 11, I would still argue that this probability is still way too high for such devastating risks. 

When I did the procedure, I was mostly basing my faith on the people around me who had gotten it, rather than digging deeper into the research, data and stories of those with complications.

A report from the FDA in 2022 highlighted some statistics around Lasik side effects/complications and they are actually quite high despite the overall short-term satisfaction rate: https://www.fda.gov/medical-devices/lasik/lasik-quality-life-collaboration-project#:~:text=Questionnaire%20with%20Filenames-,Study%20Results,halos)

The study also admits it doesn’t have much data on long-term side effects, long-term risks and satisfaction.

In general, the marketing around Lasik is that it has the highest satisfaction rate in the world, and is a quick and casual miracle. Given that Lasik is an elective, expensive, privately paid procedure, I believe that this is why many clinics don’t adequately discuss these risks or review the patient’s screening with them in detail. 

I am now in a Lasik support group with a lot of people who have both similar and different issues from the procedure.

The consequences of Lasik are honestly the hardest thing I have ever gone through, so I want to make sure the next person considering Lasik is more well-informed than I was, and knows their risks in relation to their individual screening and health history. If I could go back in time, I would’ve stuck with glasses and contacts.

All in all, the effects of Lasik on my physical and mental wellbeing have been truthfully devastating. My outcome and experience thus far is something for me to adapt to, cope with, accept and move forward from. 

Thank you for reading.

-C

[blueweave]

Ophthalmological Devices Market size by value at USD 41.2 billion in 2023.During the forecast period between 2024 and 2030, BlueWeave expects Global Ophthalmological Devices Market size to expand at a CAGR of 4.80% reaching a value of USD 57billion in 2030. Technological advancements, rising demand for the devices from emerging economies, and increasing awareness about eye health are major growth factors for Global Ophthalmological Devices Market. Rising disposable income and improved healthcare infrastructure in developing countries create growth opportunities for the market players. Key strategies include new product launches, expansion, acquisitions, partnerships, and cell-based treatments. Advancements in eye surgery, such as phacoemulsification and laser-assisted procedures, have improved treatment efficacy and vision prevention.

Opportunity – Growing adoption of innovative technologies

The Ophthalmological Devices Market across the globe is expected to grow due to advancements in nerve transplant treatments, bioengineered Corneas, artificial corneas, retinal implants, dry eye syndrome detection, intraocular lenses, contact lenses, and lasers. Wearable AR and VR goggles, AI-based therapies, and biosensors could also enhance eye tests and monitoring. Hence, rapid adoption of advanced technologies could boost the growth of Global Ophthalmological Devices Market in the coming years.

Sample Request @ https://www.blueweaveconsulting.com/report/ophthalmological-devices-market/report-sample

[bommagoni]

Dry Eye Syndrome Treatment Market Size, Share, Growth Report

[health-views-updates]

Scleral Lens Market: Global Analysis of Key Manufacturers, Dynamics & Forecast 2024-2031

The global scleral lens market has been on a remarkable trajectory, with a significant surge in its valuation over recent years. According to recent reports, the market size was valued at USD 276.15 million in 2022, and forecasts suggest it is poised to reach USD 868.54 million by 2030, exhibiting a staggering Compound Annual Growth Rate (CAGR) of 15.4% during the forecast period of 2023-2030.

Emerging Trends and Opportunities

Several factors contribute to the unprecedented growth of the scleral lens market. One prominent trend is the increasing prevalence of ocular conditions such as keratoconus, dry eye syndrome, and corneal irregularities. Additionally, advancements in technology have led to the development of innovative scleral lens designs, enhancing comfort and visual acuity for patients. Furthermore, rising awareness about the benefits of scleral lenses among both patients and healthcare professionals is driving market expansion.

Opportunities abound for market players to capitalize on these trends. Investments in research and development to further improve the design, material, and fitting process of scleral lenses can lead to the development of more effective and comfortable products. Moreover, expanding distribution networks and strategic collaborations can help companies tap into new markets and reach a broader patient base.

Download Free Sample Report: https://www.snsinsider.com/sample-request/3028

Key Drivers Propelling Growth

Several key drivers are propelling the growth of the scleral lens market. One of the primary drivers is the increasing prevalence of ocular disorders worldwide. Conditions such as keratoconus, which cause irregular corneal shape and impaired vision, are becoming more prevalent, necessitating the use of scleral lenses as an effective treatment option.

Moreover, the growing aging population, coupled with the rising incidence of conditions such as dry eye syndrome associated with age, is fueling demand for scleral lenses. Additionally, advancements in diagnostic technologies enable more precise fitting of scleral lenses, leading to better patient outcomes and driving market growth.

Challenges and Considerations

Despite the promising growth prospects, the scleral lens market faces several challenges. One significant challenge is the high cost associated with scleral lenses, which may limit access for some patients, particularly in developing regions with limited healthcare infrastructure and resources.

Furthermore, the complex fitting process and specialized expertise required for scleral lens fitting pose challenges for practitioners, potentially limiting adoption rates. Addressing these challenges requires concerted efforts from industry stakeholders to develop cost-effective solutions and expand training programs for eye care professionals.

Key Takeaways from the Market

As the scleral lens market continues to evolve, several key takeaways emerge for industry stakeholders:

Investment in Research and Development: Continued investment in R&D is crucial for driving innovation in scleral lens design and technology, enhancing patient comfort and visual outcomes.

Expansion of Distribution Networks: Companies should focus on expanding their distribution networks to reach underserved markets and capitalize on growing demand for scleral lenses.

Education and Training: Increasing awareness and providing comprehensive training for eye care professionals on scleral lens fitting and management are essential for driving market adoption.

Collaborative Partnerships: Collaboration between industry players, healthcare providers, and researchers can foster innovation and address key challenges facing the scleral lens market.

In conclusion, the scleral lens market presents significant growth opportunities driven by increasing prevalence of ocular conditions, technological advancements, and rising awareness among patients and healthcare professionals. By addressing challenges and capitalizing on emerging trends, industry stakeholders can unlock the full potential of this dynamic market, improving vision outcomes and enhancing the quality of life for patients worldwide.

[industrydelevelpoments]

Dry Eye Syndrome Market

Global Dry Eye Syndrome Market: current trends, treatment options, with a CAGR 6.30% by 2023

[spookysaladchaos]

Multi-Dose Eye Dropper, Global Market Size Forecast, Top 8 Players Rank and Market Share

Multi-Dose Eye Dropper Market Summary

According to the new market research report "Global Multi-Dose Eye Dropper Market Report 2023-2029", published by QYResearch, the global Multi-Dose Eye Dropper market size is projected to grow from USD 489 million in 2023 to USD 1334 million by 2029, at a CAGR of 18.2% during the forecast period.

A multi-dose eye dropper is a medical device commonly used to administer or instill eye medications to a patient's eyes. It is different from a single-dose eye dropper, which releases a fixed amount of liquid medicine every time it is used, while a multi-dose eye dropper allows the user to use it multiple times and can release different doses of liquid medicine as needed.

Multi-dose eye droppers typically include a container of solution and a dropper or dropper system that allows the user to release a quantity of solution by gentle pressure or twisting, which is then placed into the eye. This design allows for more precise control of the amount of drug solution and is suitable for patients who require regular eye drops, such as those who treat glaucoma, dry eye or other eye diseases. Multi-dose eye drops help ensure patients use their medications correctly while reducing waste and improving treatment effectiveness.

Figure.   Multi-Dose Eye Dropper

Figure.   Global Multi-Dose Eye Dropper Market Size (US$ Million), 2018-2029

Based on or includes research from QYResearch: Global Multi-Dose Eye Dropper Market Report 2023-2029.

Market Drivers:

Prevalence of eye diseases: With the aging population and changing lifestyles, the prevalence of eye diseases (such as glaucoma, cataracts, dry eye syndrome, etc.) is gradually increasing, which has prompted a greater demand for eye drops.

Advances in Medical Technology: Technology in the medical field continues to advance, including drug formulations, eye dropper design and manufacturing technology. These advances could improve the efficiency, accuracy and convenience of multi-dose eye droppers.

Patient convenience needs: Patients have higher expectations for convenience and comfort in treatment. Improvements in the design and functionality of multi-dose eye droppers can reduce discomfort and make it easier for patients to adhere to their medications.

Clinical Treatment Requirements: Medical professionals may require more precise dosage control to ensure the effectiveness of treatment. Multi-dose eye drops can meet these requirements and help improve treatment outcomes.

Regulations and Quality Standards: The regulatory requirements from government and regulatory agencies as well as the quality standards within the industry are constantly escalating, which prompts manufacturers to continuously improve the design and manufacturing processes of multi-dose eye droppers to comply with higher requirements.

Competitive pressure: Intensified market competition usually drives manufacturers to continuously innovate, lower product prices, and improve product quality to attract more customers.

Restraint:

Fierce competition: The multi-dose eye dropper market is highly competitive with many manufacturers vying to enter the market, resulting in fierce price competition that may have reduced the profitability of the industry.

Medical insurance coverage issues: The cost of some eye drops may not be fully covered by medical insurance, which may reduce patients' willingness to use multi-dose eye drops, thus affecting market demand.

Drug stability and storage issues: Some eye drugs are more sensitive to temperature and light, which may require more complex multi-dose eye dropper designs to ensure drug stability and storage.

Drug formulation complexity: The formulations of some eye drugs are very complex and require high-precision dose control, which may increase the design and manufacturing costs of multi-dose eye drops.

Patient compliance issues: Patients may not be treated on time because they are not used to using the eye dropper or forget to use the medication, which may affect the effectiveness of the treatment.

Regulatory requirements: The regulatory requirements for ocular medical devices and pharmaceutical eye drops are relatively strict, and manufacturers need to comply with a series of regulations and quality standards, which may increase the costs of R&D and production.

New Technologies and Alternative Treatments: As new medical technologies and treatments become available, patients and doctors may become more interested in using other treatment modalities rather than relying on eye drops.

Opportunity:

New drug development: As new ocular drugs are developed, multi-dose eye droppers with higher precision and stability are needed to ensure the effective delivery of these drugs. The industry can benefit from the market launch of these new drugs.

Digital health technology integration: Combining multi-dose eye drops with digital health technology (such as remote monitoring, smartphone apps, etc.) can improve patient compliance while providing more data for treatment monitoring and personalized medicine.

Aging Population: As the population ages and eye health problems become increasingly common, the multi-dose eye dropper market is expected to expand to cater to the needs of the elderly population.

Emerging Markets: In some emerging markets, such as Asia and Latin America, rising eye health awareness and improving medical infrastructure may create growth opportunities.

Sustainable and eco-friendly design: The market is increasingly paying attention to sustainability and environmental protection. Manufacturers can develop eco-friendly multi-dose eye drops to meet consumer needs.

Figure.   Multi-Dose Eye Dropper, Global Market Size, The Top Five Players Hold 50% of Overall Market

Based on or includes research from QYResearch: Global Multi-Dose Eye Dropper Market Report 2023-2029.

This report profiles key players of Multi-Dose Eye Dropper such as AptarGroup、Aero Pump GmbH、Nemera、Ursapharm Arzneimittel GmbH、Laboratoires Thea

In 2022, the global top five Multi-Dose Eye Dropper players account for 86% of market share in terms of revenue. Above figure shows the key players ranked by revenue in Multi-Dose Eye Dropper.

Figure.  2023-2029 Multi-Dose Eye Dropper, Global Market Size, Split by Product Segment

Based on or includes research from QYResearch: Global Multi-Dose Eye Dropper Market Report 2023-2029.

In terms of product type, Less than 5 ml is the largest segment, hold a share of 39%.

Figure.   Multi-Dose Eye Dropper, Global Market Size, Split by Application Segment

Based on or includes research from QYResearch: Global Multi-Dose Eye Dropper Market Report 2023-2029.

In terms of product application, Prescription is the largest application, hold a share of 86%.

Figure.   Multi-Dose Eye Dropper, Global Market Size, Split by Region (Production)

Based on or includes research from QYResearch: Global Multi-Dose Eye Dropper Market Report 2023-2029.

Figure.   Multi-Dose Eye Dropper, Global Market Size, Split by Region

Based on or includes research from QYResearch: Global Multi-Dose Eye Dropper Market Report 2023-2029.

About The Authors

Ziyi Fan

Lead Author

Consumer Goods,

Equipment & Parts, Packaging, etc.

About QYResearch

QYResearch founded in California, USA in 2007.It is a leading global market research and consulting company. With over 16 years’ experience and professional research team in various cities over the world QY Research focuses on management consulting, database and seminar services, IPO consulting, industry chain research and customized research to help our clients in providing non-linear revenue model and make them successful. We are globally recognized for our expansive portfolio of services, good corporate citizenship, and our strong commitment to sustainability. Up to now, we have cooperated with more than 60,000 clients across five continents. Let’s work closely with you and build a bold and better future.

QYResearch is a world-renowned large-scale consulting company. The industry covers various high-tech industry chain market segments, spanning the semiconductor industry chain (semiconductor equipment and parts, semiconductor materials, ICs, Foundry, packaging and testing, discrete devices, sensors, optoelectronic devices), photovoltaic industry chain (equipment, cells, modules, auxiliary material brackets, inverters, power station terminals), new energy automobile industry chain (batteries and materials, auto parts, batteries, motors, electronic control, automotive semiconductors, etc.), communication industry chain (communication system equipment, terminal equipment, electronic components, RF front-end, optical modules, 4G/5G/6G, broadband, IoT, digital economy, AI), advanced materials industry Chain (metal materials, polymer materials, ceramic materials, nano materials, etc.), machinery manufacturing industry chain (CNC machine tools, construction machinery, electrical machinery, 3C automation, industrial robots, lasers, industrial control, drones), food, beverages and pharmaceuticals, medical equipment, agriculture, etc.

[iruchakalyan]

The Global Dry Eye Syndrome Treatment Market was valued at USD 7 Billion in 2023 and is estimated to reach USD 13.8 Billion by 2033, growing at a CAGR of 8.4 % from 2024 to 2033.

Dry Eye Syndrome or Dry Eye Disease (DES) also known as Keratoconjunctivitis Sicca (KCS) is a very common ophthalmic condition that occurs when the person doesn’t have enough quality tears to lubricate the eyes. The symptoms of DES are a burning sensation, redness, scratching, watery eyes, light sensitivity, and mucus near the eyes.  Tear Film is the fluid that is secreted from the eyes covering them and keeping them stable on each blink preventing them from getting dry. Increasing age deteriorates the ability of the lacrimal glands to produce tears. Further, during the pandemic using screens has increased resulting in the occurrence of dry eye symptoms. According to the Dry Eye Directory, between 16.7 million and 50.2 million Americans have dry eyes i.e. approximately 15% of the population. Moreover, dry eye treatment is expected to top over USD 6.6 billion by 2027.

Economic Impact of Covid-19:

The analysis of the COVID-19 recovery trajectory provides an overview of the main strategies that industries are implementing to respond to and recover from the economic crisis. It also focuses on the post-pandemic and pre-pandemic era of the Global Dry Eye Syndrome Treatment Market through PEST analysis, SWOT, Quantitative and Qualitative analysis, Attractive analysis, and DROs. Innovations by market players and an increasing number of products will propel the growth of this market.

Trends:

Increasing in dry eye diseases is raising the demand for better treatment and eye therapies. Moreover, healthcare manufacturers are coming up with different treatments to get patients satisfaction thus fuelling the market growth.

Growing awareness in patients for better technology and developing healthcare technology will open up many opportunities in the coming years. The growing population helps in rising pollution and changing the lifestyle from traditional to modern will accelerate the demand for dry eye syndrome treatment.

Furthermore, pharmaceutical and biotechnology companies are focusing on effective treatment by investing in research and development.

The advancement of telemedicine and telehealth services makes getting easier to improve results. This trend is also accepted by doctors, healthcare providers, and surgeons to enhance treatment with consultations.

Restraining Factors:

Ignorance of dry eye disease and several patients remaining untreated due to unaware of symptoms and lack of knowledge are the main restraining factors that hamper the growth of the dry eye syndrome treatment market. 

Several companies restrict themselves from expanding due to a lack of budget and receiving approval from regulations is an expensive procedure this factor hampers the overall growth of the market.

Another growth declining factor is most of the patients do not respond to the treatment even if there are various treatments available for dry eye syndrome treatment which may restrain the adoption of this treatment in the future.

Key Players:

Novartis AG

AbbVie Inc.

AFT Pharmaceuticals

Oyster Point Pharma Inc.

Santen Pharmaceutical Co. Ltd,

Jonhson & Jonhson Services Inc.

IMO

Nicox S.A

Akorn Incorporated

Otsuka Pharmaceutical Co.,Ltd

Bausch & Lomb Pvt Ltd

GlaxoSmithKline plc

Allergan plc

FDC Limited

Lupin Limited

Boiron USA

Jamjom Pharmaceutical Co.

Others

Know More- https://nexbindinsight.com/pharmaceutical-and-healthcare/global-dry-eye-syndrome-treatment-market-by-drugs-products-distribution

[futuretonext]

The Global Dry Eye Syndrome Market is projected to grow at a CAGR of around 6.5% during the forecast period, i.e., 2023-28. The growing incidence of this disease globally has been driving the demand for its drugs in the market since the historical years, and this trend is expected to flourish during the forthcoming period as well. Owing to the rise in the geriatric population, increased awareness of the diagnosis & treatment, and an upsurge in the usage of contact lenses, high screen time, etc., are some factors aiding in enhancing the market size.

[rohit0024]

Dry Eye Syndrome Treatment Market Worth $10.13 Billion By 2030

Dry Eye Syndrome Treatment Market Growth & Trends The global dry eye syndrome treatment market size is expected to reach USD 10.13 billion by 2030, according to a new report by Grand View Research, Inc., expanding at a CAGR of 7.85% from 2023 to 2030. The growth of the market is attributed to factors such as the increasing use of screens, the rising geriatric population, and a heightened…

[ketshubhra]

Dry Eye Syndrome Market Value, Size Estimates, Share, Trend, Demand | Forecast – 2023

The development of dry eye syndrome has gained momentum in the past few decades, with their effectiveness increasing steadily. The research reports are made by Market Research Future, includes market options for development. The market is expected to grow at a CAGR of 6.6% during the forecast period (2017-2023).

Dry Eye Syndrome Market Overview:

Tears in eyes has a substantial role in lubricating the inner process and protecting eyes from infections or any other foreign matters. Dry eye syndrome is a disease where the lubrication process gets hindered due to lack of tear inflow. The global dry eye syndrome market is all ready to achieve 6.6% CAGR during the forecast period of 2017 to 2023. Market Research Future (MRFR) identified several growth opportunities that could trigger a positive effect.

Geriatric population, diabetes, rheumatoid arthritis, are few of the diseases that can trigger dry eye syndrome. Better technological installations and treatment measures can also smoothen up the growth path for the dry eye syndrome market. However, stringent norms regarding medicine manufacturing can deter the market growth.

Get a FREE Sample with Complete TOC by Considering the COVID-19 impact on Global Market @ https://www.marketresearchfuture.com/sample_request/5588

Dry Eye Syndrome Market Segmentation:

Type, diagnosis, treatment, distribution channel and end-user are segments in which the global dry eye syndrome market has been segmented by MRFR. This attempt would ensure better look into factors that can improve the market position.

Based on the type, the dry eye syndrome market comprises evaporative dry eye syndrome aqueous dry eye syndrome, and others.

Based on the diagnosis, the dry eye syndrome market comprises Schirmer test, eye exam, and others. The Schirmer test is gaining substantial acknowledgement.  

Based on the treatment, the dry eye syndrome market includes nutritional supplements, serum eye drops, lubricant eye drops, anti-inflammatory drugs segments, surgery, and others. The lubricant eye drops segment includes oily tear eye drops, ointments, preservative-free drops, and others. The anti-inflammatory drugs segment encompasses tetracyclines, corticosteroids, and others. The surgery segment has punctal occlusion, intense pulsed light therapy, and others under its purview.

Based on the distribution channel, the dry eye syndrome market consists online pharmacies, retail pharmacies, hospital pharmacies, and others. The retail pharmacies are doing good, however, the online pharmacies can gain more, if they clear stringent government policies.

Based on the end-users, the dry eye syndrome market includes hospitals, clinics, home care, and others.

Regional Analysis:

The Americas, Europe, Asia Pacific (APAC), and the Middle East & Africa (MEA) are segments that can be assessed to understand a proper functioning of the global dry eye syndrome market. This market segmentation includes a detailed study of various growth pockets, which can be taken into consideration to chart the progress route.

The Americas has significant market dominance and this is due to better diagnosis, infrastructural strength, high expenditure, and easy reimbursement policies. The presence of the US, and Canada are also expected to fetch in revenues. Cuba is also doing great in South America, along with Brazil and Argentina. The presence of several titans like Auven therapeutics, Johnson & Johnson Vision, Acadia Pharmaceutical, and others is also adding fuel to the market growth.

Europe has the second largest market and is getting benefitted from the high patient population. Healthcare sector in the region is quite robust and has a name for receiving remarkable funds from governments and private organizations. The APAC market is emerging as a market with high potential where India, China, Australia, and others are performing well. All these regions are expecting high CAGR during the forecast period.

Dry Eye Syndrome Market Competitive Landscape:

Various pharmaceuticals are impacting the global dry eye syndrome market by improving the competition in the market with strategic inclusions of processes like merger, acquisition, collaboration, and other methods. The global market is also gaining from such prolific moves. MRFR listed a few in their global dry eye syndrome market report and profiled them to get a hand over latest trends that could impact the market in the future. These companies are Novartis AG (Switzerland), Allergan (Republic of Ireland), Valent Pharmaceuticals (Canada), Otsuka Pharmaceutical Co. Ltd. (Japan), Acadia Pharmaceutical (U.S.), Johnson and Johnson Vision (U.S.), I-Med Pharma Inc. (Canada), Allostera Pharma (Canada), AFT pharmaceuticals (New Zealand), Santen Pharmaceuticals Co. Ltd., (Japan), Auven therapeutics (U.S.), Novaliq GmBh (Germany), and others.

In August 2019, results from phase 2 and 3 of the ribonucleic acid (siRNA) inhibitor tivanisiran delivered positive outcomes as a cure for dry eye syndrome. The test is getting done by researchers from Sylentis and it has been conducted in six countries. The result shows a stark improvement in the condition.

Obtain Premium Research Report Details, Considering the impact of COVID-19 @ https://www.marketresearchfuture.com/reports/dry-eye-syndrome-market-5588

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by Components, Application, Logistics and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.

In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.

[sapanas]

Dry Eye Syndrome Market Estimated To Lock An Ineffaceable Growth | 6.6% CAGR Through 2023

Dry Eye Syndrome Market 2020 Global Industry Forecast to 2023 Research Report, is latest depth analysis report on Global Dry Eye Syndrome Market Size, Trends, Share, Growth, and Regional Analysis from 2018 to 2023.

Dry Eye Syndrome Market Overview:

Tears in eyes has a substantial role in lubricating the inner process and protecting eyes from infections or any other foreign matters. Dry eye syndrome is a disease where the lubrication process gets hindered due to lack of tear inflow. The global dry eye syndrome market is all ready to achieve 6.6% CAGR during the forecast period of 2017 to 2023. Market Research Future (MRFR) identified several growth opportunities that could trigger a positive effect.

Read more news on: https://www.medgadget.com/2019/07/dry-eye-syndrome-market-size-growth-2019-global-analysis-trends-key-players-merger-share-statistics-competitive-landscape-and-regional-forecast-to-2023.html

Geriatric population, diabetes, rheumatoid arthritis, are few of the diseases that can trigger dry eye syndrome. Better technological installations and treatment measures can also smoothen up the growth path for the dry eye syndrome market. However, stringent norms regarding medicine manufacturing can deter the market growth.

Dry Eye Syndrome Market Segmentation:

Type, diagnosis, treatment, distribution channel and end-user are segments in which the global dry eye syndrome market has been segmented by MRFR. This attempt would ensure better look into factors that can improve the market position.

Based on the type, the dry eye syndrome market comprises evaporative dry eye syndrome aqueous dry eye syndrome, and others.

Based on the diagnosis, the dry eye syndrome market comprises Schirmer test, eye exam, and others. The Schirmer test is gaining substantial acknowledgement.  

Based on the treatment, the dry eye syndrome market includes nutritional supplements, serum eye drops, lubricant eye drops, anti-inflammatory drugs segments, surgery, and others. The lubricant eye drops segment includes oily tear eye drops, ointments, preservative-free drops, and others. The anti-inflammatory drugs segment encompasses tetracyclines, corticosteroids, and others. The surgery segment has punctal occlusion, intense pulsed light therapy, and others under its purview.

Based on the distribution channel, the dry eye syndrome market consists online pharmacies, retail pharmacies, hospital pharmacies, and others. The retail pharmacies are doing good, however, the online pharmacies can gain more, if they clear stringent government policies.

Based on the end-users, the dry eye syndrome market includes hospitals, clinics, home care, and others.

Dry Eye Syndrome Market Regional Analysis:

The Americas, Europe, Asia Pacific (APAC), and the Middle East & Africa (MEA) are segments that can be assessed to understand a proper functioning of the global dry eye syndrome market. This market segmentation includes a detailed study of various growth pockets, which can be taken into consideration to chart the progress route.

The Americas has significant market dominance and this is due to better diagnosis, infrastructural strength, high expenditure, and easy reimbursement policies. The presence of the US, and Canada are also expected to fetch in revenues. Cuba is also doing great in South America, along with Brazil and Argentina. The presence of several titans like Auven therapeutics, Johnson & Johnson Vision, Acadia Pharmaceutical, and others is also adding fuel to the market growth.

Europe has the second largest market and is getting benefitted from the high patient population. Healthcare sector in the region is quite robust and has a name for receiving remarkable funds from governments and private organizations. The APAC market is emerging as a market with high potential where India, China, Australia, and others are performing well. All these regions are expecting high CAGR during the forecast period.

Dry Eye Syndrome Market Competitive Landscape:

Various pharmaceuticals are impacting the global dry eye syndrome market by improving the competition in the market with strategic inclusions of processes like merger, acquisition, collaboration, and other methods. The global market is also gaining from such prolific moves. MRFR listed a few in their global dry eye syndrome market report and profiled them to get a hand over latest trends that could impact the market in the future. These companies are Novartis AG (Switzerland), Allergan (Republic of Ireland), Valent Pharmaceuticals (Canada), Otsuka Pharmaceutical Co. Ltd. (Japan), Acadia Pharmaceutical (U.S.), Johnson and Johnson Vision (U.S.), I-Med Pharma Inc. (Canada), Allostera Pharma (Canada), AFT pharmaceuticals (New Zealand), Santen Pharmaceuticals Co. Ltd., (Japan), Auven therapeutics (U.S.), Novaliq GmBh (Germany), and others.

Obtain Premium Research Report Details @ https://www.marketresearchfuture.com/reports/dry-eye-syndrome-market-5588

In August 2019, results from phase 2 and 3 of the ribonucleic acid (siRNA) inhibitor tivanisiran delivered positive outcomes as a cure for dry eye syndrome. The test is getting done by researchers from Sylentis and it has been conducted in six countries. The result shows a stark improvement in the condition.

[aditi3019]

Dry Eye Syndrome Market 2020 Global Analysis, Segments, Top Key Players, Industry Growth, Drivers and Recent Trends by Forecast to 2023

Dry Eye Syndrome Market Highlights

Increasing geriatric population, rising prevalence of the diseases like diabetes, rheumatoid arthritis, growing per capita healthcare expenditure, and changing lifestyle are the major drivers for the market growth. However, factors like stringent FDA drug approvals, lack of skilled ophthalmologists, and low per capita healthcare expenditure in the middle and low income countries are estimated to restrain the market growth during the forecast period.  

Dry Eye Syndrome Market Segmentation

The global dry eye syndrome is segmented on the basis of the type, diagnosis, treatment, distribution channel and end user.

On the basis of the type, the market is segmented into evaporative dry eye syndrome, aqueous dry eye syndrome, and others. On the basis of the diagnosis, the market is categorized into Schirmer test, eye exam, and others.  On the basis of the treatment, the market is segmented into nutritional supplements, serum eye drops, lubricant eye drops, anti-inflammatory drugs segments, surgery, and others. The lubricant eye drops segment is sub-segmented into oily tear eye drops, ointments, preservative-free drops, and others. The anti-inflammatory drugs segments segment is sub-segmented into tetracyclines, corticosteroids, and others. The surgery segment is sub-segmented into punctal occlusion, intense pulsed light therapy, and others. On the basis of distribution channel the market is segmented into hospital pharmacies, retail pharmacies, online pharmacies, and others.  On the basis of the end users, the market is segmented into hospitals, clinics, home care, and others.

Avail Free Sample @ https://www.marketresearchfuture.com/sample_request/5588

Dry Eye Syndrome Market Regional Analysis

The Americas dominates the global dry eye syndrome market owing to the presence of a well-developed healthcare sector, huge patient population, and increasing healthcare expenditure. Moreover, the presence of the major market players like Johnson & Johnson Vision, Auven therapeutics, Acadia Pharmaceutical, and others within the region boosts the market growth. Europe stands second in the dry eye syndrome market. This is attributed to the increasing availability of funds for research, a well-developed healthcare sector, huge patient and growing geriatric population. The Asia Pacific region is estimated to be the fastest growing region for the market. Economies like India, China, Australia and others within the region have huge patient population, rising healthcare expenditure facilitating the market growth. On the other hand, the Middle East & Africa has the least share in the global dry eye syndrome. Low per capita healthcare expenditure, stringent government policies, especially within the African region restrains the market growth within the region. The Middle East holds a majority of the market due to a well-developed healthcare sector and huge healthcare expenditure.

Dry Eye Syndrome Market Key Players

The key players for the global dry eye syndrome are Allergan (Republic of Ireland), Novartis AG (Switzerland), Otsuka Pharmaceutical Co. Ltd. (Japan), Valent Pharmaceuticals (Canada), Johnson and Johnson Vision (U.S.), Acadia Pharmaceutical (U.S.), Allostera Pharma (Canada), I-Med Pharma Inc. (Canada), Santen Pharmaceuticals Co. Ltd., (Japan), AFT pharmaceuticals (New Zealand), Novaliq GmBh (Germany), Auven therapeutics (U.S.), and others.

Access Report Details @ https://www.marketresearchfuture.com/reports/dry-eye-syndrome-market-5588  

[supershiba123-blog]

Artificial Tears Market Share, Trends, Growth, Future Prospects, Forecast 2019 to 2025

The global artificial tears market size was estimated to USD 1,609 million in 2018 and expected to grow a CAGR of 4.7% during the forecast period (2018-2023).  Artificial tears lubricate the ocular surface reduce tear osmolarity and protect the ocular surface from desiccation. The market is growing due to the impact of some factors such as growing dry eye syndrome (DES) coupled with geriatric population. As aging results in weaker eyesight, people are more at risk of ophthalmic disorders such as dry eye syndrome.

Request a Free Sample of our Report on Artificial Tears Market: https://www.omrglobal.com/request-sample/artificial-tears-market

The rising use of contact lenses, digital workloads, and innovation in the product creates future opportunities for the growth of the market. However, there are some factors that act as barriers for the growth of the market such as side effects of the artificial tears and lack of the awareness among people across the globe.

Global artificial tears market is segmented on the basis of types, delivery method and application. On the basis of types, the market is further diversified as cellulose derived tears, glycerin derived tears, oil-based emulsion tears and polyethylene glycol and propylene glycol-based tears. Based on the delivery method, the market is bifurcated as eye drops and ointments. According to the application, the market is further subdivided as dry eyes treatment and contact lenses moisture. Among all the types, glycerin derived tears segment is expected to hold the major share owing to its capability of keeping eyes moist for long time.

Considering the regional outlook market is divided into North America, Europe, Asia Pacific and Rest of the world. Asia Pacific creates more growth opportunities due to an increase in geriatric population and rising incidences of DES. North America and Europe covers the significant market share with their ability of advanced technology, innovation in the products and awareness among people.

A Full Report of Artificial Tears Market is Available at https://www.omrglobal.com/industry-reports/artificial-tears-market

Artificial Tears Market Segmentation

By Type

·        Cellulose Derived Tears

·        Glycerine Derived Tears

·        Oil Based Emulsion Tears

·        Polyethylene Glycol And Propylene Glycol-Based Tears

By Delivery Method

·        Eye Drops

·        Ointments

By Application

·        Dry Eyes Treatment

·        Contact Lenses Moisture

Regional Analysis

North America

·        United States

·        Canada

·        Rest Of North America

Europe

·        United Kingdom

·        France

·        Germany

·        Italy

·        Spain

·        Rest Of Europe

Asia Pacific

·        India

·        China

·        Japan

Rest of the World

Company Profiles

·        Abbott Medical Optics Inc.

·        Akorn, Inc.

·        Alcon Laboratories, Inc.

·        Allergan Plc

·        Aura Labs Ltd.

·        Bausch & Lomb Incorporation

·        Bayer Ag

·        Carl Zeiss Ag

·        Essilor International S.A

·        Hoya Corporation

·        Johnson & Johnson

·        Merck & Co., Inc.

·        Nicox S.A

·        Novagali Pharma S.A.

·        Novartis International Ag

For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/artificial-tears-market

About us:

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

For More Information, Visit https://www.omrglobal.com/

Media Contact:

Company Name: Orion Market Research

Contact Person: Mr. Anurag Tiwari

Email: info@omrglobal.com  

Contact no: +91 780-304-0404

[rohit0024]

Dry Eye Syndrome Treatment Market Worth $10.13 Billion By 2030

Dry Eye Syndrome Treatment Market Growth & Trends The global dry eye syndrome treatment market size is expected to reach USD 10.13 billion by 2030, according to a new report by Grand View Research, Inc., expanding at a CAGR of 7.85% from 2023 to 2030. The growth of the market is attributed to factors such as the increasing use of screens, the rising geriatric population, and a heightened…